Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Dec 15;155(12):2265-2276.
doi: 10.1002/ijc.35149. Epub 2024 Aug 22.

B cells critical for outcome in high grade serous ovarian carcinoma

Affiliations

B cells critical for outcome in high grade serous ovarian carcinoma

Annegé Vledder et al. Int J Cancer. .

Abstract

Recent work has shown evidence for the prognostic significance of tumor infiltrating B cells (B-TIL) in high grade serous ovarian carcinoma (HGSOC), the predominant histological subtype of ovarian cancer. However, it remains unknown how the favorable prognosis associated with B-TIL relates to the current standard treatments of primary debulking surgery (PDS) followed by chemotherapy or (neo-)adjuvant chemotherapy (NACT) combined with interval debulking surgery. To address this, we analyzed the prognostic impact of B-TIL in relationship to primary treatment and tumor infiltrating T cell status in a highly homogenous cohort of HGSOC patients. This analysis involved a combined approach utilizing histological data and high-dimensional flow cytometry analysis. Our findings indicate that while HGSOC tumors pre-treated with NACT are infiltrated with tumor-reactive CD8+ and CD4+ TIL subsets, only B-TIL and IgA plasma blasts confer prognostic benefit in terms of overall survival. Importantly, the prognostic value of B-TIL and IgA plasma blasts was not restricted to patients treated with NACT, but was also evident in patients treated with PDS. Together, our data point to a critical prognostic role for B-TIL in HGSOC patients independent of T cell status, suggesting that alternative treatment approaches focused on the activation of B cells should be explored for HGSOC.

Keywords: B cells; high grade serous ovarian cancer; tumor infiltrating lymphocytes.

PubMed Disclaimer

References

REFERENCES

    1. Colombo N, Sessa C, Du Bois A, et al. ESMO‐ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease. Ann Oncol. 2019;30(5):672‐705. doi:10.1093/annonc/mdz062
    1. Timmermans M, Sonke GS, Van de Vijver KK, van der Aa MA, Kruitwagen RFPM. No improvement in long‐term survival for epithelial ovarian cancer patients: a population‐based study between 1989 and 2014 in The Netherlands. Eur J Cancer. 2018;88:31‐37. doi:10.1016/j.ejca.2017.10.030
    1. Disilvestro P, Banerjee S, Colombo N, et al. Overall survival with maintenance Olaparib at a 7‐year follow‐up in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation: the SOLO1/GOG 3004 trial. J Clin Oncol. 2023;41(3):609‐617. doi:10.1200/JCO.22.01549
    1. Cancer Genome Atlas Research Network T. Integrated genomic analyses of ovarian carcinoma. 2012. doi:10.1038/nature10166
    1. Paijens ST, Vledder A, Loiero D, et al. Prognostic image‐based quantification of CD8CD103 T cell subsets in high‐grade serous ovarian cancer patients. Onco Targets Ther. 2021;10(1). doi:10.1080/2162402X.2021.1935104

MeSH terms

Substances

LinkOut - more resources